180 Life Sciences announces $6M registered direct offering

180 Life Sciences announced that it has entered into a definitive agreement with "a single healthcare-focused U.S. institutional investor" for the purchase and sale of 1,714,286 shares of the company’s common stock and warrants to purchase up to 2,571,429 shares of common stock at a purchase price per share and accompanying warrant of $3.50 in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.50 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.